Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pacritinib vs BAT in Myelofibrosis with Thrombocytopenia
NCT02055781Phase 3Terminated
- Sponsor
- CTI BioPharma Corp.
- Start
- Feb 2014
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 3 trial of pacritinib in myelofibrosis (MF), sponsored by CTI BioPharma Corp.. Started Feb 2014; status: terminated.
02
Drugs
pacritinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT02055781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02055781.